James J. Mancuso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
James J. Mancuso has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- James Patrick Allison
Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
5 shared publications - Stephen Tin Chi Wong
Houston Methodist Hospital
4 shared publications Xuping Li
Department of Systems Medicine and Bioengineering, Houston Methodist Research Institute, Houston, TX, USA
4 shared publicationsZhen Zhao
Department of Radiology, Zhong-Da Hospital, Southeast University, Nanjing, China
4 shared publications- Nana-Ama A. S. Anang
Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3 shared publications Stephen T. C. Wong
Houston Methodist Research Institute, Houston, TX 77030 USA
3 shared publications
Latest Publications
- 1 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (9) , 1739-1749
Translational Challenges and Opportunities in mRNA Cancer Vaccines
Messenger RNA (mRNA) cancer vaccines have progressed rapidly, with personalized platforms such as mRNA-4157 and BNT122 demonstrating feasibility, safety, and durable immune activity but limited scalability. Off-the-shelf constructs, including BNT111 and BNT113, enable faster, broader deployment, yet they risk reduced precision or immune tolerance. These complementary approaches reveal key translational dualities: personalization versus shared antigen (off-the-shelf), potency versus safety, and speed versus durability. This mini-review synthesizes emerging clinical evidence and outlines strategies such as modular vaccine design, prime–boost vaccination regimens, and adaptive trial frameworks to reconcile these trade-offs and advance scalable, durable mRNA vaccines for broad oncologic impact. Significance: By dissecting the competing design pressures that shape mRNA vaccine performance, this mini-review proposes integrative strategies, spanning modular architectures, prime–boost regimens, and adaptive trials, to reconcile immunologic potency with manufacturability and safety, charting a roadmap toward next-generation cancer vaccines.
- 1 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (9) , 1739-1749
Translational Challenges and Opportunities in mRNA Cancer Vaccines
Messenger RNA (mRNA) cancer vaccines have progressed rapidly, with personalized platforms such as mRNA-4157 and BNT122 demonstrating feasibility, safety, and durable immune activity but limited scalability. Off-the-shelf constructs, including BNT111 and BNT113, enable faster, broader deployment, yet they risk reduced precision or immune tolerance. These complementary approaches reveal key translational dualities: personalization versus shared antigen (off-the-shelf), potency versus safety, and speed versus durability. This mini-review synthesizes emerging clinical evidence and outlines strategies such as modular vaccine design, prime–boost vaccination regimens, and adaptive trial frameworks to reconcile these trade-offs and advance scalable, durable mRNA vaccines for broad oncologic impact. Significance: By dissecting the competing design pressures that shape mRNA vaccine performance, this mini-review proposes integrative strategies, spanning modular architectures, prime–boost regimens, and adaptive trials, to reconcile immunologic potency with manufacturability and safety, charting a roadmap toward next-generation cancer vaccines.
- Open Access
Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4+ T-cells, and CD8+ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS-ICOSL pathway, and are enriched for ICOS+ Th1-like CD4+ T cells and ICOSL-high cDC1s. CD8+ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon gamma-responsive program that sustains CD8+ T-cell function and prevents dysfunction. Functionally, ICOSL+ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.
Open AccessMacrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4+ T-cells, and CD8+ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS-ICOSL pathway, and are enriched for ICOS+ Th1-like CD4+ T cells and ICOSL-high cDC1s. CD8+ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon gamma-responsive program that sustains CD8+ T-cell function and prevents dysfunction. Functionally, ICOSL+ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.
- Open Access
- 9 January 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (2)
Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1
The effects of T cell differentiation arising from immune checkpoint inhibition targeting cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) on the immunological memory response remain unclear. Our investigation into the effects of anti-CTLA-4 and anti-PD-1 on memory T cell formation in mice reveals that memory T cells generated by anti-CTLA-4 exhibit greater expansion, cytokine production, and antitumor activity than those from anti-PD-1. Notably, anti-CTLA-4 preserves more T cell factor-1 (TCF-1)+ T cells during priming, while anti-PD-1 leads to more thymocyte selection-associated high mobility group box (TOX)+ T cells. Experiments using conditional Tcf7 - or Tox -knockout mice highlight that TCF-1 is essential for the memory response generated by anti-CTLA-4, whereas TOX deletion alone in T cells has no effect on the response to anti-PD-1. Deepening our understanding of how checkpoint inhibition affects memory response is crucial for advancing our understanding of the enduring impacts of these immunotherapies on the immune system.
- 9 January 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (2)
Open AccessAnti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1
The effects of T cell differentiation arising from immune checkpoint inhibition targeting cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) on the immunological memory response remain unclear. Our investigation into the effects of anti-CTLA-4 and anti-PD-1 on memory T cell formation in mice reveals that memory T cells generated by anti-CTLA-4 exhibit greater expansion, cytokine production, and antitumor activity than those from anti-PD-1. Notably, anti-CTLA-4 preserves more T cell factor-1 (TCF-1)+ T cells during priming, while anti-PD-1 leads to more thymocyte selection-associated high mobility group box (TOX)+ T cells. Experiments using conditional Tcf7 - or Tox -knockout mice highlight that TCF-1 is essential for the memory response generated by anti-CTLA-4, whereas TOX deletion alone in T cells has no effect on the response to anti-PD-1. Deepening our understanding of how checkpoint inhibition affects memory response is crucial for advancing our understanding of the enduring impacts of these immunotherapies on the immune system.
- Open Access
- 26 June 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (27)
Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy
Immune checkpoint therapies (ICT) improve overall survival of patients with cancer but may cause immune-related adverse events (irAEs) such as myocarditis. Cytotoxic T lymphocyte-associated antigen 4 immunoglobulin fusion protein (CTLA-4 Ig), an inhibitor of T cell costimulation through CD28, reverses irAEs in animal models. However, concerns exist about potentially compromising antitumor response of ICT. In mouse tumor models, we administered CTLA-4 Ig 1) concomitantly with ICT or 2) after ICT completion. Concomitant treatment reduced antitumor efficacy, while post-ICT administration improved efficacy without affecting frequency and function of CD8 T cells. The improved response was independent of the ICT used, whether CTLA-4 or PD-1 blockade. The frequency of Tregs was significantly decreased with CTLA-4 Ig. The resulting increased CD8/Treg ratio potentially underlies the enhanced efficacy of ICT followed by CTLA-4 Ig. This paradoxical mechanism shows that a CTLA-4 Ig regimen shown to reduce irAE severity does not compromise antitumor efficacy.
- 26 June 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (27)
Open AccessPost-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy
Immune checkpoint therapies (ICT) improve overall survival of patients with cancer but may cause immune-related adverse events (irAEs) such as myocarditis. Cytotoxic T lymphocyte-associated antigen 4 immunoglobulin fusion protein (CTLA-4 Ig), an inhibitor of T cell costimulation through CD28, reverses irAEs in animal models. However, concerns exist about potentially compromising antitumor response of ICT. In mouse tumor models, we administered CTLA-4 Ig 1) concomitantly with ICT or 2) after ICT completion. Concomitant treatment reduced antitumor efficacy, while post-ICT administration improved efficacy without affecting frequency and function of CD8 T cells. The improved response was independent of the ICT used, whether CTLA-4 or PD-1 blockade. The frequency of Tregs was significantly decreased with CTLA-4 Ig. The resulting increased CD8/Treg ratio potentially underlies the enhanced efficacy of ICT followed by CTLA-4 Ig. This paradoxical mechanism shows that a CTLA-4 Ig regimen shown to reduce irAE severity does not compromise antitumor efficacy.
- Open Access
- 21 October 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (45) , 22699-22709
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Immune checkpoint blockade therapy targets T cell-negative costimulatory molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1). Combination anti–CTLA-4 and anti–PD-1 blockade therapy has enhanced efficacy, but it remains unclear through what mechanisms such effects are mediated. A critical question is whether combination therapy targets and modulates the same T cell populations as monotherapies. Using a mass cytometry-based systems approach, we comprehensively profiled the response of T cell populations to monotherapy and combination anti–CTLA-4 plus anti–PD-1 therapy in syngeneic murine tumors and clinical samples. Most effects of monotherapies were additive in the context of combination therapy; however, multiple combination therapy-specific effects were observed. Highly phenotypically exhausted cluster of differentiation 8 (CD8) T cells expand in frequency following anti–PD-1 monotherapy but not combination therapy, while activated terminally differentiated effector CD8 T cells expand only following combination therapy. Combination therapy also led to further increased frequency of T helper type 1 (Th1)-like CD4 effector T cells even though anti–PD-1 monotherapy is not sufficient to do so. Mass cytometry analyses of peripheral blood from melanoma patients treated with immune checkpoint blockade therapies similarly revealed mostly additive effects on the frequencies of T cell subsets along with unique modulation of terminally differentiated effector CD8 T cells by combination ipilimumab plus nivolumab therapy. Together, these findings indicate that dual blockade of CTLA-4 and PD-1 therapy is sufficient to induce unique cellular responses compared with either monotherapy.
- 21 October 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (45) , 22699-22709
Open AccessCombination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Immune checkpoint blockade therapy targets T cell-negative costimulatory molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1). Combination anti–CTLA-4 and anti–PD-1 blockade therapy has enhanced efficacy, but it remains unclear through what mechanisms such effects are mediated. A critical question is whether combination therapy targets and modulates the same T cell populations as monotherapies. Using a mass cytometry-based systems approach, we comprehensively profiled the response of T cell populations to monotherapy and combination anti–CTLA-4 plus anti–PD-1 therapy in syngeneic murine tumors and clinical samples. Most effects of monotherapies were additive in the context of combination therapy; however, multiple combination therapy-specific effects were observed. Highly phenotypically exhausted cluster of differentiation 8 (CD8) T cells expand in frequency following anti–PD-1 monotherapy but not combination therapy, while activated terminally differentiated effector CD8 T cells expand only following combination therapy. Combination therapy also led to further increased frequency of T helper type 1 (Th1)-like CD4 effector T cells even though anti–PD-1 monotherapy is not sufficient to do so. Mass cytometry analyses of peripheral blood from melanoma patients treated with immune checkpoint blockade therapies similarly revealed mostly additive effects on the frequencies of T cell subsets along with unique modulation of terminally differentiated effector CD8 T cells by combination ipilimumab plus nivolumab therapy. Together, these findings indicate that dual blockade of CTLA-4 and PD-1 therapy is sufficient to induce unique cellular responses compared with either monotherapy.
- Open Access
- 15 February 2019
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 35 (19) , 3709-3717
Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction
Drug combinations that simultaneously suppress multiple cancer driver signaling pathways increase therapeutic options and may reduce drug resistance. We have developed a computational systems biology tool, DrugComboExplorer, to identify driver signaling pathways and predict synergistic drug combinations by integrating the knowledge embedded in vast amounts of available pharmacogenomics and omics data. This tool generates driver signaling networks by processing DNA sequencing, gene copy number, DNA methylation and RNA-seq data from individual cancer patients using an integrated pipeline of algorithms, including bootstrap aggregating-based Markov random field, weighted co-expression network analysis and supervised regulatory network learning. It uses a systems pharmacology approach to infer the combinatorial drug efficacies and synergy mechanisms through drug functional module-induced regulation of target expression analysis. Application of our tool on diffuse large B-cell lymphoma and prostate cancer demonstrated how synergistic drug combinations can be discovered to inhibit multiple driver signaling pathways. Compared with existing computational approaches, DrugComboExplorer had higher prediction accuracy based on in vitro experimental validation and probability concordance index. These results demonstrate that our network-based drug efficacy screening approach can reliably prioritize synergistic drug combinations for cancer and uncover potential mechanisms of drug synergy, warranting further studies in individual cancer patients to derive personalized treatment plans. DrugComboExplorer is available at https://github.com/Roosevelt-PKU/drugcombinationprediction. Supplementary data are available at Bioinformatics online.
- 15 February 2019
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 35 (19) , 3709-3717
Open AccessDriver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction
Drug combinations that simultaneously suppress multiple cancer driver signaling pathways increase therapeutic options and may reduce drug resistance. We have developed a computational systems biology tool, DrugComboExplorer, to identify driver signaling pathways and predict synergistic drug combinations by integrating the knowledge embedded in vast amounts of available pharmacogenomics and omics data. This tool generates driver signaling networks by processing DNA sequencing, gene copy number, DNA methylation and RNA-seq data from individual cancer patients using an integrated pipeline of algorithms, including bootstrap aggregating-based Markov random field, weighted co-expression network analysis and supervised regulatory network learning. It uses a systems pharmacology approach to infer the combinatorial drug efficacies and synergy mechanisms through drug functional module-induced regulation of target expression analysis. Application of our tool on diffuse large B-cell lymphoma and prostate cancer demonstrated how synergistic drug combinations can be discovered to inhibit multiple driver signaling pathways. Compared with existing computational approaches, DrugComboExplorer had higher prediction accuracy based on in vitro experimental validation and probability concordance index. These results demonstrate that our network-based drug efficacy screening approach can reliably prioritize synergistic drug combinations for cancer and uncover potential mechanisms of drug synergy, warranting further studies in individual cancer patients to derive personalized treatment plans. DrugComboExplorer is available at https://github.com/Roosevelt-PKU/drugcombinationprediction. Supplementary data are available at Bioinformatics online.
- 1 January 2017
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 365-368
Deep learning analytics for diagnostic support of breast cancer disease management
Breast cancer continues to be one of the leading causes of cancer death among women. Mammogram is the standard of care for screening and diagnosis of breast cancer. The American College of Radiology developed the Breast Imaging Reporting and Data System (BI-RADS) lexicon to standardize mammographic reporting to assess cancer risk and facilitate biopsy decision-making. However, because substantial inter-observer variability remains in the application of the BI-RADS lexicon, including inappropriate term usage and missing data, current biopsy decision-making accuracy using the unstructured free text or semi-structured reports varies greatly. Hence, incorporating novel and accurate technique into breast cancer decision-making data is critical. Here, we combined natural language processing and deep learning methods to develop an analytic model that targets well-characterized and defined specific breast suspicious patient subgroups rather than a broad heterogeneous group for diagnostic support of breast cancer management.
- 1 January 2017
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 365-368
Deep learning analytics for diagnostic support of breast cancer disease management
Breast cancer continues to be one of the leading causes of cancer death among women. Mammogram is the standard of care for screening and diagnosis of breast cancer. The American College of Radiology developed the Breast Imaging Reporting and Data System (BI-RADS) lexicon to standardize mammographic reporting to assess cancer risk and facilitate biopsy decision-making. However, because substantial inter-observer variability remains in the application of the BI-RADS lexicon, including inappropriate term usage and missing data, current biopsy decision-making accuracy using the unstructured free text or semi-structured reports varies greatly. Hence, incorporating novel and accurate technique into breast cancer decision-making data is critical. Here, we combined natural language processing and deep learning methods to develop an analytic model that targets well-characterized and defined specific breast suspicious patient subgroups rather than a broad heterogeneous group for diagnostic support of breast cancer management.
- Open Access
- 14 April 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (8) , 2094-2104
In VivoVisualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors
The activation of the epithelial-to-mesenchymal transition (EMT) program is a critical step in cancer progression and metastasis, but visualization of this process at the single-cell level, especially in vivo, remains challenging. We established an in vivo approach to track the fate of tumor cells based on a novel EMT-driven fluorescent color switching breast cancer mouse model and intravital two-photon laser scanning microscopy. Specifically, the MMTV-PyMT, Rosa26-RFP-GFP, and Fsp1-Cre triple transgenic mouse model was used to monitor the conversion of RFP-positive epithelial cells to GFP-positive mesenchymal cells in mammary tumors under the control of the Fsp1 (ATL1) promoter, a gate-keeper of EMT initiation. RFP-positive cells were isolated from the tumors, sorted, and transplanted into mammary fat pads of SCID mice to monitor EMT during breast tumor formation. We found that the conversion from RFP- to GFP-positive and spindle-shaped cells was a gradual process, and that GFP-positive cells preferentially localized close to blood vessels, independent of tumor size. Furthermore, cells undergoing EMT expressed high levels of the HGF receptor, c-Met, and treatment of RFP-positive cells with the c-Met inhibitor, cabozantinib, suppressed the RFP-to-GFP conversion in vitro. Moreover, administration of cabozantinib to mice with palpable RFP-positive tumors resulted in a silent EMT phenotype whereby GFP-positive cells exhibited reduced motility, leading to suppressed tumor growth. In conclusion, our imaging technique provides a novel opportunity for visualizing tumor EMT at the single-cell level and may help to reveal the intricacies underlying tumor dynamics and treatment responses. Cancer Res; 76(8); 2094–104. ©2016 AACR.
- 14 April 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (8) , 2094-2104
Open AccessIn VivoVisualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors
The activation of the epithelial-to-mesenchymal transition (EMT) program is a critical step in cancer progression and metastasis, but visualization of this process at the single-cell level, especially in vivo, remains challenging. We established an in vivo approach to track the fate of tumor cells based on a novel EMT-driven fluorescent color switching breast cancer mouse model and intravital two-photon laser scanning microscopy. Specifically, the MMTV-PyMT, Rosa26-RFP-GFP, and Fsp1-Cre triple transgenic mouse model was used to monitor the conversion of RFP-positive epithelial cells to GFP-positive mesenchymal cells in mammary tumors under the control of the Fsp1 (ATL1) promoter, a gate-keeper of EMT initiation. RFP-positive cells were isolated from the tumors, sorted, and transplanted into mammary fat pads of SCID mice to monitor EMT during breast tumor formation. We found that the conversion from RFP- to GFP-positive and spindle-shaped cells was a gradual process, and that GFP-positive cells preferentially localized close to blood vessels, independent of tumor size. Furthermore, cells undergoing EMT expressed high levels of the HGF receptor, c-Met, and treatment of RFP-positive cells with the c-Met inhibitor, cabozantinib, suppressed the RFP-to-GFP conversion in vitro. Moreover, administration of cabozantinib to mice with palpable RFP-positive tumors resulted in a silent EMT phenotype whereby GFP-positive cells exhibited reduced motility, leading to suppressed tumor growth. In conclusion, our imaging technique provides a novel opportunity for visualizing tumor EMT at the single-cell level and may help to reveal the intricacies underlying tumor dynamics and treatment responses. Cancer Res; 76(8); 2094–104. ©2016 AACR.
- 1 February 2016
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 368-371
DrugMoaMiner: A computational tool for mechanism of action discovery and personalized drug sensitivity prediction
Heterogeneity of genomic instabilities among individual patients is believed to be a major cause of drug response heterogeneity. Cancer patients who are sensitive to anti-cancer drugs are often re-examined to understand the unknown mechanism of action (MoA) of given drugs. For example, a non-small cell lung cancer (NSCLC) patient was reported to be responsive to Dasatinib treatment and remained cancer-free four years later. Though follow-up genomic analysis showed the patient bears an inactivating BRAF [1]mutation in the tumor, the MoA remains unclear. There are two challenges in uncovering the MoA. First, Dasatinib is a kinase inhibitor, which often has many protein targets. Second, the downstream MoA signaling pathways regulated by these targets are too complicated to delineate. Currently, there is no computational tool that can effectively address both challenges. To fill this gap, we developed a computational tool DrugMoaMiner (Drug MoA Miner) that can be used to identify the comprehensive set of kinase inhibitor targets; delineate the underlying drug MoA; and predict personalized sensitivity to a given drug based on an individual's gene expression profiles. We applied the DrugMoaMiner to lung cancer cell lines to uncover the potential MoA signaling network of Dasatinib sensitivity; our result is in agreement with previous protein data analysis. Moreover, we can predict Dasatinib response of an independent set of NSCLC cell lines using the MoA signaling network uncovered.
- 1 February 2016
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 368-371
DrugMoaMiner: A computational tool for mechanism of action discovery and personalized drug sensitivity prediction
Heterogeneity of genomic instabilities among individual patients is believed to be a major cause of drug response heterogeneity. Cancer patients who are sensitive to anti-cancer drugs are often re-examined to understand the unknown mechanism of action (MoA) of given drugs. For example, a non-small cell lung cancer (NSCLC) patient was reported to be responsive to Dasatinib treatment and remained cancer-free four years later. Though follow-up genomic analysis showed the patient bears an inactivating BRAF [1]mutation in the tumor, the MoA remains unclear. There are two challenges in uncovering the MoA. First, Dasatinib is a kinase inhibitor, which often has many protein targets. Second, the downstream MoA signaling pathways regulated by these targets are too complicated to delineate. Currently, there is no computational tool that can effectively address both challenges. To fill this gap, we developed a computational tool DrugMoaMiner (Drug MoA Miner) that can be used to identify the comprehensive set of kinase inhibitor targets; delineate the underlying drug MoA; and predict personalized sensitivity to a given drug based on an individual's gene expression profiles. We applied the DrugMoaMiner to lung cancer cell lines to uncover the potential MoA signaling network of Dasatinib sensitivity; our result is in agreement with previous protein data analysis. Moreover, we can predict Dasatinib response of an independent set of NSCLC cell lines using the MoA signaling network uncovered.